NASDAQ:ARVN

Arvinas Stock Insider Trading

Healthcare > Biotechnology

Buy ARVN

*Your capital is at risk

$7.70

-0.300 (-3.75%)

At Close: Jun 03, 2026

Arvinas Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 69.51. In total, the insiders bought 2.92M and sold 134.55K ARVN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	69.51
● Buy	2.92M shares
● Sell	134.55K shares
75% Buy Activity Weak Positive Correlation
Sell Signal Low Confidence May 11, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 69.51. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 25, 2025 Buy	Stock Option (right to buy) A-Award	Bain Linda Director	Director	23 105 Value: $180.2K
Jun 25, 2025 Buy	Common Stock A-Award	Bain Linda Director	Director	16 025 Value: $125.0K
Jun 25, 2025 Buy	Stock Option (right to buy) A-Award	Young John D Director	Director	23 105 Value: $180.2K
Jun 25, 2025 Buy	Common Stock A-Award	Young John D Director	Director	16 025 Value: $125.0K
Jun 25, 2025 Buy	Stock Option (right to buy) A-Award	Morrison Briggs Director	Director	23 105 Value: $180.2K
Jun 25, 2025 Buy	Common Stock A-Award	Morrison Briggs Director	Director	16 025 Value: $125.0K
Jun 25, 2025 Buy	Stock Option (right to buy) A-Award	Smaldone Alsup Laurie Director	Director	23 105 Value: $180.2K
Jun 25, 2025 Buy	Common Stock A-Award	Smaldone Alsup Laurie Director	Director	16 025 Value: $125.0K
Jun 24, 2025 Sell	Common Stock S-Sale	Saik Andrew Chief Financial Officer	C-Suite Officer	5 700 Value: $43.4K
Jun 24, 2025 Sell	Common Stock S-Sale	Saik Andrew Chief Financial Officer	C-Suite Officer	5 700 Value: $43.4K
Jun 17, 2025 Sell	Common Stock S-Sale	Cacace Angela M Chief Scientific Officer	Officer	2 583 Value: $19.3K
Jun 17, 2025 Sell	Common Stock S-Sale	Cacace Angela M Chief Scientific Officer	Officer	2 583 Value: $19.3K
May 09, 2025 Buy	Common Stock A-Award	Loomis David K Chief Accounting Officer	Officer	11 825 Value: $78.2K
May 09, 2025 Buy	Stock Option (right to buy) A-Award	Loomis David K Chief Accounting Officer	Officer	18 100 Value: $119.6K
May 09, 2025 Buy	Common Stock A-Award	Saik Andrew Chief Financial Officer	C-Suite Officer	59 600 Value: $394.0K
May 09, 2025 Buy	Stock Option (right to buy) A-Award	Saik Andrew Chief Financial Officer	C-Suite Officer	91 000 Value: $601.5K
May 09, 2025 Buy	Common Stock A-Award	Cacace Angela M Chief Scientific Officer	Officer	59 600 Value: $394.0K
May 09, 2025 Buy	Stock Option (right to buy) A-Award	Cacace Angela M Chief Scientific Officer	Officer	91 000 Value: $601.5K
May 09, 2025 Buy	Common Stock A-Award	Berkowitz Noah Chief Medical Officer	Officer	59 600 Value: $394.0K
May 09, 2025 Buy	Stock Option (right to buy) A-Award	Berkowitz Noah Chief Medical Officer	Officer	91 000 Value: $601.5K
May 09, 2025 Buy	Stock Option (right to buy) A-Award	Cacace Angela M Chief Scientific Officer	Officer	91 000 Value: $601.5K
May 09, 2025 Buy	Common Stock A-Award	Cacace Angela M Chief Scientific Officer	Officer	59 600 Value: $394.0K
May 09, 2025 Buy	Stock Option (right to buy) A-Award	Saik Andrew Chief Financial Officer	C-Suite Officer	91 000 Value: $601.5K
May 09, 2025 Buy	Common Stock A-Award	Saik Andrew Chief Financial Officer	C-Suite Officer	59 600 Value: $394.0K
May 09, 2025 Buy	Stock Option (right to buy) A-Award	Loomis David K Chief Accounting Officer	Officer	18 100 Value: $119.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ARVINAS INC.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV...

Read Full Profile Here